Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Antiviral Res. 2017 Jun 20;145:24–32. doi: 10.1016/j.antiviral.2017.06.015

Fig. 3. Anti-EBOV activities of cp15 and cp19 in macrophages and HFF cells.

Fig. 3

Dose-response titrations were evaluated in human PBMC derived macrophages against infectious EBOV/Kikwit infection (red) or in cell toxicity assay (green) for cp15 (a) and cp19 (b). Dose-response titrations were evaluated in human foreskin fibroblasts (HFF) against infectious EBOV/Kikwit infection (red) or in cell toxicity assay (green) for cp15 (c) and cp19 (d). Data are means ± SD (n = 2) for macrophage test and means ± SD (n = 4) for HFF test. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)